About
Regentis Biomaterials is a tissue-repair company developing and commercializing a hydrogel platform for the repair of damaged tissue. Its current efforts are focused on orthopedic treatments using degradable hydrogel implants to regenerate damaged or diseased tissue. The company's first commercial product is GelrinC, a cell-free, off-the-shelf hydrogel implant for the treatment of painful injuries to articular knee cartilage. After standard microfracture, the hydrogel is injected as a liquid and conforms to the lesion's size, shape, and depth, with no cutting or press fitting required to fill the lesion. After brief exposure to UV light, the hydrogel becomes a semisolid implant tightly integrated with the surrounding tissue and bone with no fibrin glue necessary to secure it in place. The implant acts as a scaffold, gradually eroding over time as new cartilage takes its place. GelrinC is completely resorbed in vivo within 6 to 12 months. The manufacturing process of GelrinC meets strict international safety, quality, and biocompatibility standards, including GMP and ISO 13485.
Funding history · 3 rounds · $43.5M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did Regentis Biomaterials become a publicly traded company?
- Regentis Biomaterials became a publicly traded company on NASDAQ in September 2025, with its IPO closing in December 2025.
- What was the total amount raised by Regentis Biomaterials through its funding rounds?
- Regentis Biomaterials raised a total of $43.5 million through its funding rounds, with the last round being a Series D in February 2016.
- Which investors participated in Regentis Biomaterials' Series D funding round?
- In February 2016, Regentis Biomaterials' Series D funding round included investors such as General Oriental Investments, Haisco, Medica Venture Partners, SCP Vitalife, and T3.
- What was the acquisition event involving Regentis Biomaterials in May 2023?
- In May 2023, Regentis Biomaterials announced a business combination with OceanTech Acquisitions I Corp. in a $95 million deal, which would lead to Regentis becoming publicly listed on Nasdaq.
- When did Regentis Biomaterials receive CE Mark approval for GelrinC in Europe?
- Regentis Biomaterials received European CE Mark approval for its product GelrinC in August 2017.
- What significant regulatory approval did Regentis Biomaterials receive in September 2016?
- In September 2016, Regentis Biomaterials received IDE (Investigational Device Exemption) approval for its pivotal GelrinC clinical trial.
- What was a key development regarding GelrinC production in March 2026?
- In March 2026, Regentis Biomaterials developed and patented a new solvent-free manufacturing process that increased GelrinC production yield by 400%.
- What was the strategic appointment made by Regentis Biomaterials in February 2026?
- In February 2026, Regentis Biomaterials appointed Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC progressed towards commercial launch in Europe and advanced in its U.S. Phase III FDA Trial.
- What was reported about GelrinC's performance in January 2026?
- In January 2026, Regentis' GelrinC demonstrated a breakthrough in regenerating native-like cartilage structure in knee repair, confirmed by MRI results using a validated, regulator-accepted method.